Holen Sie sich die Stockscreener-App
81.75
2.34%
-1.96
Vorhandelsmarkt:
82.29
0.54
+0.66%
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Korlym improves results for diabetes patients taking GLP-1 drugs - Cushing's Disease News
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) - Yahoo Finance
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT to resubmit NDA for relacorilant in Cushing's syndrome, stock up - MSN
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
CORT Stock Rises 42% in a Month: Here's What You Should Know - The Globe and Mail
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diab - GuruFocus
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diabetes Treatment - GuruFocus
Geode Capital Management LLC Acquires 734,646 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® - Lelezard
Legal & General Group Plc Decreases Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Stock On Fire: Up 36% With 12-Day Winning Streak - Trefis
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics Stock 12-Day Winning Spree: Stock Climbs 36% - Trefis
Corcept Therapeutics chief development officer sells $1.41m stock By Investing.com - Investing.com Australia
Corcept Therapeutics chief development officer sells $1.41m stock - Investing.com UK
Adrenocortical Carcinoma Market Forecast Signals Robust - openPR.com
Adrenocortical Carcinoma Market Forecast Signals Robust Industry Growth Through 2036 – DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck, Enterome, Bristol-Myers Squibb, UNICANCE - Barchart
Corcept (NASDAQ: CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? - The Motley Fool
Corcept Faces Amended Qui Tam Complaint After DOJ Exit - The Globe and Mail
Corcept Therapeutics president Sean Maduck sells $1.76m in stock - Investing.com UK
11-Day Rally Sends Corcept Therapeutics Stock Up 32% - Trefis
Corcept Therapeutics Stock Surges 32%, With A 11-Day Winning Spree - Trefis
Corcept Therapeutics president Sean Maduck sells $1.76m in stock By Investing.com - Investing.com Australia
Corcept Therapeutics CFO sells $2.8m in company stock - Investing.com
Corcept Therapeutics CFO sells $2.8m in company stock By Investing.com - Investing.com Australia
Corcept (NASDAQ: CORT) officer reports stock grants and tax share withholding - Stock Titan
Corcept (NASDAQ: CORT) CDO acquires 1,754 shares via grant and purchase plan - Stock Titan
Corcept (CORT) officer sells 25K shares after option exercise under 10b5-1 plan - Stock Titan
Corcept Therapeutics (CORT) CFO executes 40,000-share option exercise-and-sale under 10b5-1 plan - Stock Titan
Corcept (NASDAQ: CORT) CBO reports equity awards and tax-share withholding - Stock Titan
[8-K] CORCEPT THERAPEUTICS INC Reports Material Event - Stock Titan
DOJ Declines Intervention in Qui Tam Suit Against Corcept; Relator Amends Complaint - TradingView
Corcept Therapeutics Stock 10-Day Winning Spree: Stock Climbs 29% - Trefis
Corcept Therapeutics Stock On Fire: Up 29% With 10-Day Winning Streak - Trefis
Corcept (NASDAQ: CORT) CEO trust sale and 600,000-share gifts disclosed - Stock Titan
Corcept (CORT) insider resale notice: 20,000 shares via option exercise (06/02/2026) - Stock Titan
Corcept Therapeutics Stock On Fire: Up 21% With 9-Day Winning Streak - Trefis
H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
H.C. Wainwright reiterates Corcept stock rating on ASCO data By Investing.com - Investing.com Canada
Corcept Therapeutics Stock Surges 28%, With A 9-Day Winning Spree - Trefis
CORT (NASDAQ: CORT) Rule 144 notice: 160,000 shares via Stifel - Stock Titan
Joseph Belanoff sells 66,198 CORT shares; Form 144 filed (CORT) - Stock Titan
Corcept Therapeutics Insider Sold Shares Worth $325,000, According to a Recent SEC Filing - Moomoo
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Corcept Therapeutics Insider Sold Shares Worth $4,918,944, According to a Recent SEC Filing - Moomoo
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):